A retrospective analysis was performed to better understand the risk of PJP among patients receiving BTK inhibitor therapy. Among patients on prophylaxis, the overall prevalence of infection was 3.4%; ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback